Strategic Partnerships Neos' proprietary modified-release drug delivery platforms create opportunities to partner with larger pharmaceutical companies to expand ADHD and CNS portfolios through co development, licensing, or manufacturing collaborations for XR products.

Manufacturing Services With demonstrated extended-release manufacturing capabilities, Neos can monetize through contract manufacturing and fill finish services for other developers pursuing XR therapies, delivering scalability and recurring revenue.

Distribution Access The merger with Aytu BioScience offers a potential commercialization channel across clinics, specialty pharmacies, and payer networks, enabling faster market access for XR ADHD therapies and related products.

Product Format Advantage Branded XR candidates in ODT or oral suspension formats provide formulation diversity that can meet patient adherence and payer needs, strengthening sales pitches to clinicians and payers.

Financing Partnerships A modest revenue base and available funding position Neos to pursue licensing, co marketing, or distribution deals to accelerate growth and generate near term revenue through partnerships.